Discontinuation of Humulin® and Humalog® insulin vials
Medicines Supply Notification: Discontinuation of Humulin® and Humalog® insulin vials
gps.northcentrallondon.icb.nhs.ukI currently don't have tool access in this turn to fetch live updates. I can share the latest widely reported information and guidance I know up to now, and help you interpret it. If you want, I can still search the web in a subsequent turn.Here’s the latest information I can provide based on publicly reported sources up to now.
- Humulin R (regular insulin) 100 units/mL in 10 mL vials has faced manufacturing and supply changes in several markets. In some regions, Lilly indicated adjustments to vial formats and ongoing supply considerations for Humulin R products, with guidance about when to initiate or switch therapy for patients. Note that these developments are country-specific and depend on local supply chains and regulatory decisions.[1][3]
- In the UK/NHS context, there have been Medicines Supply Notifications regarding discontinuation of certain Humulin and Humalog vial formats, with timelines indicating remaining stock and recommendations for clinicians to migrate patients to alternative devices where appropriate (e.g., pen injectors). This can affect availability of Humulin R 10 mL vials in the near term in some areas, though regional stock varies.[1]
- For patients or prescribers, common guidance during transitions includes: avoid initiating new patients on discontinued vial formats, assess feasibility of switching to pen devices or alternative insulins, and ensure proper patient education about timing, dosing, and storage during any switch. Short-acting insulins like Humulin R have pharmacodynamics that begin within minutes to hours and last several hours, which must be managed carefully during any transition.[5][1]
Illustrative example: If a clinic is transitioning a patient from Humulin R 10 mL vials to a pen-based insulin, clinicians typically arrange a structured switch plan with dose equivalence, accommodate any vial-to-pen dose conversion, and provide training on recognizing hypoglycemia and storage changes. This kind of plan aligns with published supply notifications and common pharmacist guidance described in the sources above.[3][1]
Would you like me to search for the very latest updates specific to your location in London, or pull the official NHS Medicines Supply Notifications and current FDA/EMEA labeling for Humulin R to confirm exact stock statuses and alternative options? I can also summarize recommended steps for a patient in transition if that would help.